Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

The population attributable fraction as a measure of the impact of warfarin pharmacogenetic testing.

Pharmacogenomics - 1 Aug 2012

Chan Sze Ling, Suo Chen, Chia Kee Seng, Teo Yik Ying

Abstract excerpt

AIM: We aimed to estimate the population impact of warfarin pharmacogenetic testing (WPGT) across multiple populations. MATERIALS & METHODS: We used the expanded International Warfarin Pharmacogenetics Consortium data set and genotype frequencies from HapMap to simulate dose distributions for each CYP2C9/VKORC1 genotype combination in the different races, and calculated the population attributable fraction as a...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Anticoagulants
Share to Aryl Hydrocarbon Hydroxylases
Share to Blood Coagulation

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cytochrome P-450 CYP2C9

Share to HapMap Project

Share to Mixed Function Oxygenases

Share to Vitamin K Epoxide Reductases

Share to Warfarin

Source

Identifiers

PMID: 22920395
DOI: 10.2217/pgs.12.104

Genes

VKORC1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

The population attributable fraction as a measure of the impact of warfarin pharmacogenetic testing.PMID 22920395Read ↗

Warfarin Pharmacogenetics Reevaluated: Subgroup Analysis Reveals a Likely Underestimation of the Maximum Pharmacogenetic Benefit by Clinical Trials.Semantic proximity Read ↗

Warfarin pharmacogenetics: does more accurate dosing benefit patients?Semantic proximity Read ↗

The future of warfarin pharmacogenetics in under-represented minority groups.Semantic proximity Read ↗

STRATEGIES FOR EQUITABLE PHARMACOGENOMIC-GUIDED WARFARIN DOSING AMONG EUROPEAN AND AFRICAN AMERICAN INDIVIDUALS IN A CLINICAL POPULATION.Semantic proximity Read ↗

Validation of warfarin pharmacogenetic algorithms in 586 Han Chinese patients.Semantic proximity Read ↗

Race influences warfarin dose changes associated with genetic factors.Semantic proximity Read ↗

Establishment of a Han Chinese-specific pharmacogenetic-guided warfarin dosing algorithm.Semantic proximity Read ↗

Extending and evaluating a warfarin dosing algorithm that includes CYP4F2 and pooled rare variants of CYP2C9.Semantic proximity Read ↗

Genotype-guided dosing of warfarin through modeling and simulation.Semantic proximity Read ↗

Pharmacogenetic-guided and clinical warfarin dosing algorithm assessments with bleeding outcomes risk-stratified by genetic and covariate subgroups.Semantic proximity Read ↗

Development and validation wise assessment of genotype guided warfarin dosing algorithm in Indian population.Semantic proximity Read ↗

Estimation of the warfarin dose with clinical and pharmacogenetic data.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.